Cardiovascular Toxicity Induced by Antitumoral Drugs: Risk Assessment and Early Diagnosis. CARDIOTOX Registry

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

3400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is multicenter, post-authorization, observational and ambispective

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry

NCT06086132

Cancer Related Cardiovascular Toxicity

RECRUITING

Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care

NCT03882580

Cardiovascular Complication Cardiovascular Insufficiency Cardiac Complication +5 more

UNKNOWN

Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients

NCT04962425

Cardiac Toxicity Antitumor Drugs Breast Cancer

UNKNOWN

Chronic Toxicities Related to Treatment in Patients With Localized Cancer

NCT01993498

Breast Cancer Nos Metastatic Recurrent Early Lung Cancer

RECRUITING NA

Biomarkers to Predict Cancer Therapy-related Cardiotoxicity

NCT06353191

Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cardiovascular toxicity produced by antitumoral drugs has a considerable impact in life wellness and prognosis of cancer patients, which can imply the suspension of the desired antitumoral treatment or even risk the patient´s life. The development of a risk score for these patients, as well as specific methodology for early detection of cardiotoxicity would therefore be a great outcome to trigger new strategies for the monitoring of these patients. Currently there is a lack of a clinical score to predict cardiotoxicity risk. Therefore, there is an urgent need to identify new myocardial injury biomarkers and novel imaging parameters for measuring ventricular function that would increase the sensitivity of the traditional methods used for the early detection of cardiotoxicity.

The objectives of the present study are the following:

* Identify the factors related with cardiotoxicity risk produced by antitumoral drugs.
* Assess the utility of clinical, biological and functional parameters for the early detection of cardiotoxicity produced by antitumoral drugs.

The study is a multicenter one, observational and ambispective. We will include all the patients assessed by the Oncology and Haematology Departments in each participant hospital that are about to initiate or are undergoing chemotherapy with any of the drugs specified in the study protocol. Patients will be monitorized during the treatment, undergoing an echocardiography study and a blood sample collection in each clinical timepoint. All these parameters will hopefully shed some light for the development of a clinical risk score as well as identifying new early biomarkers for cardiotoxicity.

The initial follow-up in this phase of the study will be 2 years

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Toxicity Induced by Antitumoral Drugs

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient under study condition

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients\> 18 years with indicated antitumor chemotherapy.
* Estimated survival ≥ 6 months
* No oxygen dependence
* No contraindication for taking the study target antitumor agents.
* No exclusion of patients with risk factors or previous heart disease.
* No exclusion of patients with previous cancer, previous antitumor treatment, current antitumor treatment, previous or current radiotherapy.
* No exclusion of patients with previous cardiovascular toxicity

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No